Open AccessA double-blind, placebo-controlled Homoeopathic Pathogenetic Trial of Nanocurcumin 6X
Author(s) -
Niranjan Mohanty,
Sujata Kumari Choudhury,
Santosh Kumar Jena
Publication year - 2015
Publication title -
indian journal of research in homeopathy/indian journal of research in homoeopathy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.119
H-Index - 2
eISSN - 2320-7094
pISSN - 0974-7168
DOI - 10.4103/0974-7168.166381
Subject(s) - placebo , medicine , traditional medicine , homeopathy , alternative medicine , double blind , drug trial , clinical trial , pathology
Background: A double-blind, randomized, placebo-controlled Homoeopathic Pathogenetic Trial (HPT) of Nanocurcumin was conducted using the accepted guidelines, Ethical Committee approval, and scientific documentation. The standardized potentization method was adopted to enhance the quality of the pathogenetic trial. Various statistical calculations were used for evaluation of the symptoms.Aim: The aim of the study was to conduct an HPT of Nanocurcumin 6X, a nano-substance in dilution.Materials and Methods: The drug Nanocurcumin 6X was proved through double-blind, placebo-controlled method. The trial was done in 6X potency on 30 healthy provers who were screened by their pretrial medical examinations and routine laboratory investigations. Of 30 provers, 7 were on placebo and 23 were on drug. Medicine was prepared according to the principles of trituration given in Homoeopathic Pharmacopeia of India. The signs and symptoms generated during the trial period were noted by the provers and decoded and compiled afterwards.Results: Of 23 provers who were on verum 17 provers manifested symptoms and out of 7 provers who were on placebo 2 manifested symptoms.Conclusion: The drug pathogenesis evolved indicates its therapeutic use in sinusitis, migraine, dyspepsia, constipation, diarrhoea, dysmenorrhoea, pharyngitis, bronchitis, etc